Astria Therapeutics Inc
ATXS
Company Profile
Business description
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Contact
22 Boston Wharf Road
10th Floor
BostonMA02210
USAT: +1 617 349-1971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
78
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,758.40 | 98.20 | -1.11% |
| CAC 40 | 8,119.02 | 51.07 | -0.63% |
| DAX 40 | 23,590.52 | 286.03 | -1.20% |
| Dow JONES (US) | 46,590.24 | 557.24 | -1.18% |
| FTSE 100 | 9,675.43 | 22.94 | -0.24% |
| HKSE | 26,086.20 | 298.08 | -1.13% |
| NASDAQ | 22,708.07 | 192.52 | -0.84% |
| Nikkei 225 | 49,432.56 | 891.35 | -1.77% |
| NZX 50 Index | 13,389.85 | 109.19 | -0.81% |
| S&P 500 | 6,672.41 | 61.70 | -0.92% |
| S&P/ASX 200 | 8,487.60 | 91.20 | -1.06% |
| SSE Composite Index | 3,952.16 | 19.87 | -0.50% |